Zoom Logo

Expanding COVID-19 vaccination coverage among key populations and people living with HIV - Shared screen with speaker view
Mpho Dimene
21:52
Mpho Dimene
Rebecca Dirks
21:56
Rebecca Dirks, FHI 360, US
Sumita Taneja
21:58
Sumita Taneja, FHI 360 India Country Office
Bitra George
22:03
Bitra George, Country Director, FHI 360/India
Hally Mahler
22:03
Hally Mahler, FHI 360, US
Papa Alioune GUEYE
22:14
Papa Alioune Gueye, Solthis , Senegal
Cameron Wolf
22:15
Cameron Wolf, USAID/DC
John Macom
22:15
John Macom, FHI 360, Cambodia
Teresita Bagasao
22:21
Teresita Bagasao, EpiC-HIV, Philippines
RICHMOND TAGOE
22:26
Richmond Tagoe, Sanford Health-Ghana
Parsa Sanjana
22:26
Parsa Sanjana, FHI 360, USA
Rafaela Egg
22:30
Rafaela Egg, FHI 360 consultant, South Africa
Pamela Donggo
22:34
Pamela Donggo, JSI/ USAID RHITES-North, Lango Project (Uganda)
Kenisha Jefferson
22:35
Kenisha Jefferson, FHI 360, Washington DC
Bhawani Dahal
22:36
Bhawani Prasad Dahal, AFAO/SKPA Program, Bangkok
Phal Sophat
22:38
My name is Phal Sophat FHI360 Cambodia
Chavia Zagita Trufani
22:39
Chavia Trufani, FHI 360, Indonesia
Mpho Dimene
22:40
Mpho Dimene, EpiC Lesotho
Paul Amechi
22:46
Paul Amechi, Heartland Alliance Nigeria
Carey Johnson
22:48
Carey Johnson, Altair Consulting, Boston MA
pallavi dani
22:48
Pallavi Dani, FIND, India
Bhagawan Shrestha
22:55
Hi everyone, Bhagawan from FHI 360 Nepal
Madison Mellish
23:02
Madison Mellish, Palladium, Washington, DC
Kristina Grabbe
23:02
Kristina Grabbe, Jhpiego, US
Aarti Gor
23:03
Aarti Gor, FHI360, India Country Office
Rachel Eersel
23:07
Rachel Eersel, Suriname
Irma Tasya
23:13
Irma Anintya, Indonesia
Chavia Zagita Trufani
23:14
Irfan Riswan, FHI 360, Indonesia
Emily Headrick
23:14
Emily Headrick, EpiC/FHI360, NC(US)
Sunni Wenson
23:28
Sunni Wenson, FHI 360, Zambia
Scholastica Tembo
23:36
Scholastica Tembo, FHI360, Zambia
TIMOTHY MASTRO
24:01
Hi - Tim Mastro, CSciO - FHI 360 HQ
Mame Diarra Faye
24:31
Mame Faye USAID Senegal
Kate Douglass
24:39
Kate Douglass, EpiC/FHI360, DC/HQ
Mulenga Chilambwe
25:00
Mulenga chilambwe fhi 360 zambia
John Macom
25:07
Rajesh Khanal, EpiC/FHI360 Nepal
Joseph Vyankandondera
25:09
Joseph from UNFPA regional office
Tom Boyles
25:26
Tom Boyles Right to Care, South Africa
Pradeep Thakur
25:39
Pradeep Kumar Thakur, Sr. Technical Advisor, SI, EpiC.
Hally Mahler
26:01
Tom Newton-Lewis, HSS team, FHI360
Siti Sulami
26:03
Siti Sulami, Associate Director, SI, EpiC Indonesia
Chirantani Baroi
27:05
Chirantani Dey Baroi, Communication Specialist and Consultant for STAPI/FHI360 (ARPA Program)
Rose Wilcher
30:31
Please drop any questions for George into the chat.
Thérèse Essomba
31:17
Mbezele Essomba Thérèse from Cameroon
Lynette Hardy
32:29
Lynette Hardy from EpiC Guyana
Endale Tilahun
33:04
Endale W Tilahun, PSI Eswatini
Alick Samona
33:11
alick samona from zambia
Andrea Surette
33:35
Dr. Siberry, can you please talk about any interactions between the COVID vaccines and hormone therapy, ART, or TB drugs? Do PLHIV need to stop taking medications before or after COVID vaccination?
Christopher Akolo
34:16
Chris Akolo, FHI 360, Washington, DC
Mame Diarra Faye
36:37
any preference in vaccine type
George Siberry
37:52
Hi @Mame. Any COVID vaccine authorized for use can be used in PLHIV.
Mulenga Chilambwe
38:03
usually PLHIV with cd4 count less than 200 susceptible to co infection, is their specific recommendation on which type of vaccine for PLHIV?
George Siberry
39:13
Hi @Mulenga. PLHIV with CD4<200 should get an additional dose of COVID vaccine to complete their primary series - but any of the authorized/approved COVID vaccines can be used.
Chavia Zagita Trufani
39:14
Hi, what are the known major barriers for PLHIV in accessing COVID-19 vaccination?
Kenisha Jefferson
42:58
Hi @Chavia--Padmavathi's presentation highlights some of barriers PLHIV encounter when trying to access vaccines
Andrea Surette
43:12
EpiC India summarized their work vaccinating key populations and PLHIV in this success story: https://www.fhi360.org/sites/default/files/media/documents/resource-epic-increasing-vaccination-india-success-story.pdf
Chavia Zagita Trufani
44:10
Great, thank you @Kenisha :)
Rose Wilcher
44:24
EpiC's technical guide for expanding vaccine access among PLHIV and key populations is available here: https://www.fhi360.org/sites/default/files/media/documents/epic-guide-covid-19-vaccination-plhiv.pdf
Mulenga Chilambwe
45:03
Thank you @ George
Papa Alioune GUEYE
45:15
thanks is that available in french?
Rose Wilcher
45:51
Not yet, but we do plan to get it translated.
Siti Sulami
46:03
Thanks Rose!
Phal Sophat
46:51
does EpiC have any guidance for PLHIV should not do before and after Varina
Phal Sophat
47:56
Does EpiC have any guidance for PLHIV and KPs should not do before and after Vaccinated?
Rafaela Egg
48:58
Is there any evidence that the promotion of COVID vaccination amongst KPs increase the uptake of HIV services in turn?
Emily Headrick
49:38
What mechanism or approach did you use to understand the specific drivers of vaccine hesitancy and incorporate them into ongoing programs? Surveys or reports from peer counselors? Other approaches?
Mpho Dimene
50:15
kindly request slides after presentation mdimene@pactworld.org
Hally Mahler
52:13
Hello Phal... as outlined by George the only issue concerns whether or not PLHIV are on corticosteroids. Otherwise there is nothing for PLHIV to do before or after vaccine that differs from the general population... so nothing before, and perhaps treating any small side effects with fever/pain reducers afterward.
George Siberry
57:53
Agree with Hally's advice. (Even for people receiving high-dose corticosteroids for treatment of certain opportunistic illnesses, the concern with COVID vaccines is not safety; rather, it's the potential for poorer protective response to the vaccine. These will be uncommon scenarios.)
Moses Bateganya
59:21
Given the challenges with CD4 to determine PLHIV for are at elevated risk, is there a way to add covid-19 testing to the advanced disease package for PLHIV maybe based on clinical criteria or should program just prioritize vaccination for all newly diagnosed PLHIV
Phal Sophat
59:35
through experience in Cambodia 🇰🇭 a lot of people's drank alcohol before vaccinations and after vaccinated . what should we tell them about drink alcohol when they had vaccinated ?
Mulenga Chilambwe
01:02:28
I noticed that 4047 PLHIV were vaccinated, but what is the proportional achievement against the Tx cur of the PLHIV for the period January and February?
George Siberry
01:04:28
@Phal, thanks for this question. I think there are two main points: (1) alcohol, even in excess, whether before or after vaccine should NOT be a barrier to getting COVID vaccine. Frankly, there are VERY few legitimate medical/health reasons to not get a COVID vaccine. (2) The program can, of course, take the opportunity of interacting with such clients to counsel them about the many other health benefits of limiting their alcohol intake and support them to work on that.
Tom Boyles
01:04:54
@Moses I don't see Covid testing being added to the AHD package of care. I assume you are concerned with persistent covid- in reality the only treatment in LRS is ART and everyone with AHD needs that
Hadiza Khamofu
01:06:01
Mulenga, we started implementation Jan 22 and do not have complete vaccines status on all PLHIV yet. We collect this information as clients come for drug pick to facilities or any of our community drug pick sites
Bukola ESAN
01:06:37
Good afternoon everyone. I am Engr. Bukola ESAN, a Consultant Biomedical Engineer from Nigeria.I am glad to be here
Phal Sophat
01:07:14
thank you so much for your response the questions
Mulenga Chilambwe
01:07:35
thank you Hadiza
George Siberry
01:08:10
@Tom, I might add that there is no reason for routine COVID testing in people with AHD - should still be driven by symptoms or exposures. I completely support your point about the importance of supporting folks with AHD to take on effective ART ASAP! People with AHD would also benefit from an extra dose of COVID vaccine in their primary series.
Siti Sulami
01:08:39
any evidence vaccine among TBHIV coinfection?
Cameron Wolf
01:09:10
@Travis - given the overwhelming request ($3.3 Million) vs. action (just $300 thousand, only 10%) - how has OutRight coordinated and partnered with other donors to reach the unmet need?
Chavia Zagita Trufani
01:12:15
one of the barriers that we face here in Indonesia is that some health care workers believe that PLHIV requires to achieve some level of control (e.g. CD4 level, viral load) in order to receive COVID-19. Thus, in some occasions, PLHIVs were turned away because they were required to get CD4/viral load tests before getting vaccinated. Is there any other country experiencing the same thing? And how did you overcame this?
Moses Bateganya
01:13:10
Given the limited quantities of vaccines and the fact that many PLHIV are on effective therapy, is there adequate justification to prioritize PLHIV on effective ART above other population groups such as the elderly?
Hally Mahler
01:13:32
Chavia... it sounds like you need to invest in making sure health care workers have received some training/technical updates on PLHIV and Covid vaccines. There isn't an easy answer other than sensitization and training.
Christopher Akolo
01:14:01
Perhaps COVID-19 vaccination should be part of the standard package of services for all PLHIV, particularly those newly diagnosed.
Kenisha Jefferson
01:15:57
Hi Rafaela--Padmavathi sent the following note regarding your question: Promotion of COVID vaccination among CBO staff and volunteers put them at reduced risk for COVID there by ensuring continuity of service delivery even during COVID surges
George Siberry
01:19:03
@Siti, I am not aware of dedicated studies of COVID vaccines in people with TB/HIV; I'm also not aware that TB coinfection alters the recommendation to provide COVID vaccine to PLHIV. (In fact, the presence of TB makes it more likely that the person may have lower CD4 or less well controlled HIV.... which would make it even more important to provide COVID). [If I can find something more specific about COVID in TB/HIV, I will share with the organizers after this webinar.]
Phal Sophat
01:19:25
thanks all presenters very interested presentation